Skip to content
Markets News
Stocks1 min read

Johnson & Johnson in Advanced Talks to Buy Ollin Biosciences

Makkler Newsroom
November 16, 2026 · Based on reporting by Dünya

The proposed deal could reach $3.4 billion, including cash and payments tied to milestones for Ollin’s experimental eye drug.

Key takeaways

  • Johnson & Johnson is in advanced talks to acquire Ollin Biosciences for up to $3.4 billion.
  • The proposed terms include $2.2 billion in cash and up to $1.2 billion in milestone payments.

Johnson & Johnson is in advanced talks to acquire Ollin Biosciences in a deal that could be worth up to $3.4 billion, according to Dünya. No final agreement has been announced, and the discussions could still fall through.

The proposed terms include $2.2 billion in cash for Ollin shareholders and up to $1.2 billion in payments tied to development milestones. The deal centers on OLN324, an experimental treatment for two retinal diseases that has not received regulatory approval.

As of Friday’s close, Johnson & Johnson shares were at $285.75, up 0.79% from the previous close.

Topics
JNJOllin Biosciences
Further reading

This article was produced with the help of AI technology. Based on reporting by the outlets listed above.

Comments (0)

Log in to join the discussion.Log in

No comments yet - be the first to weigh in.